Research record

Heterogeneity of Response to PD-1/PD-L1 Inhibitors in Elderly Patients with Advanced NSCLC under the Background of Immunosenescence and Intervention Strategies

Research record published by Chinese Journal of Lung Cancer, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.

Plain-language guide

Five questions to ask about this record

What this is
research-record record from Chinese Journal of Lung Cancer.
Why it may matter
It matched a longevity topic and may show how that evidence area is developing.
Evidence
Automated topic match 100%; this is not a medical rating.
Main limitation
One research record does not prove safety, effectiveness, or usefulness for an individual.
What changed
Source metadata was published or refreshed March 1, 2026.
Where to verify
Open the primary source below for methods, population, results, and limitations.
Published
March 1, 2026
Journal
Chinese Journal of Lung Cancer
Authors
Yurong HUANG, Yuan WANG, Aojiao WEI, Yulu XIONG, Mingzhi DUAN, Tongyao XU, Wenjie HE
DOI
10.3779/j.issn.1009-3419.2026.101.05
Evidence class
research-record
Record status
published
Match confidence
100%
Source feed
Directory of Open Access Journals
Automated source synopsis

Research record published by Chinese Journal of Lung Cancer, indexed because it matched monitored longevity research terms. Inclusion in this index does not establish that an intervention is effective or safe.

Evidence snapshot

What the source actually supports

Evidence stage
Research record
Study design
Open-access journal article
Evidence population
Not reported in reusable metadata
Participants
Not reported
Population
Not reported
Duration
Not reported
Intervention
Comparator
Not reported
Outcomes measured
Reported result
No reusable finding-level result is available in this record.

Main limitationBibliographic metadata identifies the record but does not provide enough reusable detail to summarize its population, comparison, findings, or effect size.

Safety and approvalThis index record does not establish safety, effectiveness, dose, or suitability for any person. A publication record is not a regulatory approval or treatment recommendation.

Source supportBibliographic citation metadata and controlled indexing terms only. Read the linked source for methods and results.

Evidence stage · research-recordThis describes the study type, not whether an intervention is safe or effective.
Lab or animalHuman studyRandomized trialEvidence synthesis
Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Immune ageing · 100%Title contains controlled term: immunosenescence. Source terminology contains: immunosenescence. Title supplies longevity context: senescence, elderly.

Automated source check 90% · update recency 85%. These figures help sort records; they are not medical ratings.

BibTeX · RIS

immune aging
Read the original source →Export JSON